
Where Do You Stand on the Sitting-Rising Test?
The Evolution of Fitness Metrics
I was a teenager when I first read the book Aerobics , by Dr Kenneth Cooper. Motivated to try out what I had learned, I convinced our high-school PE teacher to apply Cooper's 12-minute test to our class by running laps around the basketball court to estimate aerobic fitness. A few years later (1974), when entering medical school, I was fortunate to have my VO 2 effectively measured in a maximal test undertaken in the university's exercise physiology laboratory. Soon I was working in the same lab as a research assistant.
It did not take too long to realize that fitness involved more than 'just' aerobic capacity. I first studied flexibility and proposed the Flexitest as an assessment tool to evaluate the maximal physiologic passive range of motion in several joint movements. But it was only in the late 1990s, after several brainstorming sessions with my wife, Denise Sardinha (who holds a PhD in physical education), and many trials, that the SRT became ready for application. For scientific purposes, my 1999 publication describing the SRT established its birth date.
Anatomy of the Sitting-Rising Test
Teaching and mentoring graduate students and practicing sports and exercise medicine in CLINIMEX in Rio de Janeiro, Brazil, has provided me with the opportunity to experiment with the SRT in different scenarios and types of populations, and to formally determine its concurrent validity and interobserver/intraobserver reliability. In July 1998, we formally introduced the assessment as part of the CLINIMEX evaluation protocol and, since then, we have safely applied it to over 9000 individuals ranging in age from 6 to 102 years with a wide variety of clinical and fitness-related conditions.
The CLINIMEX exercise cohort has provided us the opportunity to propose sex- and age-reference data from our assessment tools and, in combination with the official data from the state, to conduct several observational studies on nonaerobic fitness and mortality. From its birth in 1999 to now, the SRT has emerged as a tool to simultaneously assess all nonaerobic fitness components — muscle strength and power, flexibility, balance, and body composition — and SRT performance across these components has proven to be a significant predictor of mortality.
The main features of the SRT are:
It's safe, simple, and quick to apply.
The protocol of evaluation is well standardized.
The evaluator has standardized verbal instructions to present to test-takers.
Scoring is simple (0-10 scale), and even self-scoring can be reliable for many adults.
Scores are easily understood by the individual being tested.
Scores are reliable and validly assess nonaerobic fitness.
No equipment is needed to perform the test or assess the result.
Time does not need to be measured and speed of execution is not a factor.
The test can be performed by people of any age, from preschoolers to the super-aged.
The limitations and contraindications for its application are clearly specified.
Good scientific evidence supports its association with mortality.
Traditionally, men have had greater strength and power than women, but women tend to be more flexible than men, which somewhat balances scores for men and women in similar age groups.
Responding to Reader Reactions
I'll now address some additional issues brought by Medscape readers.
'What information does the score add? Compared to vital signs, clinical impressions, medical history, executive function, and other clinical measures, is there additional value in the score? Compared to grip strength, serum albumin, or creatinine, does the new score improve reliable estimation of mortality risk? I would like to know more before I ask my patients to sit on the floor.'
Nonaerobic fitness does have prognostic implications for survival in middle-aged and older adults who were able to be evaluated by the SRT, even after controlling for several clinical covariates, such as presence of coronary artery disease, arterial hypertension, dyslipidemia, obesity, and diabetes. The hazard ratio obtained with SRT scores exceeds those obtained with each one of the components of nonaerobic fitness in our other studies, and it is by far higher than those relating to many of the classical risk factors or basic clinical signs (eg, resting heart rate), making the SRT a very powerful clinical tool. Indeed, I have suggested several times in lectures and interviews that the SRT can be easily incorporated into all health consultations.
"None had physical or clinical limitations that restricted their participation in the fitness tests."
As with most studies using fitness tests (eg, treadmill studies), we have excluded those with major locomotor or neurologic limitations from our mortality studies. However, other researchers found the SRT clinically useful for some specific cases, such as post-total knee arthroplasty, multiple sclerosis, or chronic stroke. Although we have not specifically studied healthspan, health-related quality of life, or autonomy, in my clinical experience scores on the SRT are strongly related to a better or positive profile in these areas.
"I think that cultures where people squat often would excel at this. Not so much for people who were raised to sit in chairs their entire lives."
Of course, our latest study has several limitations, as it was a single-center study and restricted to a specific population. Crossing the legs (or ankles) to sit and to rise is not mandatory, but most individuals feel that this is the best way to perform the SRT. Some individuals, especially young children, can prefer to sit down without crossing their legs and do very well with it; this is perfectly OK with the protocol. I agree that people in Asian cultures will likely have more facility to obtain comparable higher SRT scores. Squatting and sitting on the floor seems to be much easier and common to some specific populations in Asia and, coincidentally or not, they tend to live longer.
"Yet another 'test' which proves that physically fit people tend to live longer — something doctors haven't known for the past 100 years!"
A final thought about how the SRT compares with other 'similar' fitness tests. The 'five times sit-to-stand test' (FTSTS test), presumably first proposed in 1985, is quite well known and similar assessments have been advocated by the US Centers for Disease Control and Prevention. However, several relevant issues differentiate the two tests.
The FTSTS test requires a 'standard height' chair and an evaluator trained to adequately and precisely time the execution of the tasks with a stopwatch, which makes it more complicated to administer and introduces potential for error. The SRT is also much simpler to score and interpret, as the FTSTS depends on mean power in five executions. The FTSTS does not depend much on body flexibility or balance, while SRT scoring is very much influenced by these components of nonaerobic fitness. And importantly, no situation in daily life demands an individual stand and sit in a chair five times as fast as possible, while sitting and rising from the floor at 'natural speed' is a common action that we learn early and routinely practice over the course of our life.
Beauty in Simplicity
We all know physicians have a large array of advanced clinical tools at their disposal, including imaging, laboratory testing, and genetic testing. Over the years, I have studied, admired, and used sophisticated technology, as appropriate, for diagnosing and prognosing in my medical practice. I am fully receptive to these concerns and understand how challenging it can be to recognize that a simple test requiring zero equipment has significant utility in identifying middle-aged and older individuals who are at higher risk for premature death.
However, I urge readers to remember the amazing (and likely unreplaceable) merits of observing and examining the patient. These "basics" are a foundational pillar of medicine. The SRT is another great example of how a simple, yet science-backed, test can be so informative and powerful.
So, why don't you try it? What is your SRT score? Get your friends and family to join in and compare their SRT scores to sex- and age-reference values. Perhaps after getting acquainted with the SRT, you will consider including it as an assessment tool in your daily clinical practice.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
11 minutes ago
- Medscape
Brain Stimulation Promising for Progressive Aphasia
Transcranial magnetic stimulation (TMS) may augment standard language therapy to help slow the progression of primary progressive aphasia (PPA), a neurodegenerative disorder that erodes communication. In a randomized sham-controlled clinical trial, 6 months of active intermittent theta-burst TMS plus language therapy improved or mitigated decline in regional brain metabolism, trained language abilities, functional impairment, and neuropsychiatric symptoms in adults with PPA. The study was published online on August 11 in JAMA Network Open . Added Value? PPA is a heterogeneous clinical syndrome marked by progressive speech and/or language impairment. Most cases stem from frontotemporal degeneration or Alzheimer's disease. There are currently no effective drug treatments, although speech-language therapy has proven to be helpful. TMS can induce changes in cortical excitability, potentially promoting the reorganization of language networks, and has shown promise as adjunctive treatment for post-stroke aphasia. Previous studies examining the short-term effects of TMS on PPA reported 'encouraging' results, but the longer-term effects, beyond more than a few weeks of intervention, have not been examined, until now. For the study, the researchers led by Jordi Matias-Guiu, MD, PhD, with the Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain, recruited 63 adults with early-stage PPA (42 women; mean age, 72 years). Participants were randomized (2:1) to either active intermittent theta-burst TMS or sham TMS for 6 months, immediately followed by evidence-based language therapy for PPA. The trial consisted of a 24-week treatment that included a 2-week intensive course, in which active TMS or sham TMS combined with language therapy was applied daily, followed by a maintenance phase in which the same stimulation was applied weekly for 22 weeks. Participants were assessed at baseline, 3 months after the start of the treatment, and at the end of the treatment (6 months following baseline). The main outcome was the standardized uptake value ratio (SUVR) on FDG PET imaging in the left hemisphere, assessed at baseline and at 6 months (immediately following the intervention). Feasible, Effective Option The primary outcome was positive with higher adjusted mean SUVR in the active group than in the sham TMS group (0.78 vs 0.77; P = .046). Active TMS was also associated with significant improvement on all secondary language outcomes at 6 months, including the mini linguistic state examination, with an adjusted mean difference at 6 months of 7.71 ( P = .002). Patients in the sham group worsened on this measure compared with those in the active group. Active TMS also led to improvement in confrontation naming of trained words, which improved by a mean 23.8 points in active recipients compared with sham TMS recipients. Functional independence also benefited, with daily-living scores falling (indicating better performance) by 5.4 points in the active group compared with the sham TMS group. Neuropsychiatric symptoms eased as well, with a 4-point advantage on the neuropsychiatric inventory scale. There were no significant differences in the number of adverse events. Adherence to treatment protocol was high (92%). 'Overall, these findings suggest that the combination of TMS and language therapy is a feasible and effective treatment option for PPA,' the researchers concluded. They said future studies should investigate the potential for TMS paired with an evidence-based speech-language intervention to sustain or extend these benefits beyond 6 months.
Yahoo
39 minutes ago
- Yahoo
Next-Gen Heart Trial and Raised Outlook Might Change the Case for Investing in TransMedics (TMDX)
TransMedics Group, Inc. recently received conditional FDA approval to begin its Next-Generation OCS ENHANCE Heart trial, the largest heart transplant preservation study to date, and reported strong quarterly results with increased full-year revenue guidance. This combination of clinical and financial milestones highlights TransMedics' efforts to expand both the use and market reach of its organ transplant technology. We'll assess how the launch of this major clinical trial could impact TransMedics' broader investment outlook and future growth drivers. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. TransMedics Group Investment Narrative Recap To be a TransMedics Group shareholder, you need to believe that advances in organ preservation technology and successful clinical outcomes will drive broader adoption, fueling long-term growth. The FDA's conditional approval for the Next-Generation OCS ENHANCE Heart trial is an important development that could influence short-term sentiment but does not fundamentally change the biggest immediate catalyst: further clinical validation of OCS platforms; nor does it remove the largest risk, which remains the possibility of underwhelming trial results or advances from competitors. Among the company's recent updates, the revised full-year 2025 revenue guidance, now set at US$585 million to US$605 million, stands out. This more optimistic outlook directly relates to expanded clinical activity and increasing OCS system adoption, reinforcing the importance of future clinical milestones as potential inflection points for both revenue acceleration and investor confidence. On the other hand, investors should be aware of challenges if next-generation OCS trials fail to meet… Read the full narrative on TransMedics Group (it's free!) TransMedics Group is projected to reach $913.8 million in revenue and $151.1 million in earnings by 2028. This outlook assumes annual revenue growth of 19.8% and nearly doubles earnings, with an increase of $79.4 million from the current $71.7 million. Uncover how TransMedics Group's forecasts yield a $142.29 fair value, a 12% upside to its current price. Exploring Other Perspectives Nine fair value estimates from the Simply Wall St Community range from US$65.24 to US$308.09 per share. With heightened expectations pinned to new clinical trials, these wide opinions reflect just how differently you and other investors may assess future business risks and opportunities. Explore 9 other fair value estimates on TransMedics Group - why the stock might be worth over 2x more than the current price! Build Your Own TransMedics Group Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your TransMedics Group research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free TransMedics Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TransMedics Group's overall financial health at a glance. Interested In Other Possibilities? Our top stock finds are flying under the radar-for now. Get in early: The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TMDX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
41 minutes ago
- Medscape
Race, Ethnicity Influences Depression Risk in Vitiligo
TOPLINE: In a study, Black and Hispanic patients with vitiligo were at a significantly greater risk for depression than control individuals, which was not the case for White and Asian patients with vitiligo. METHODOLOGY: Researchers conducted a retrospective cross-sectional study of 1087 patients with vitiligo using electronic health records from the National Institutes of Health All of Us Program between 2018 and 2024. They were compared with 5435 individuals without vitiligo, matched by age, sex, race/ethnicity, education, income, and insurance status. In both groups, the mean age was 63.2 years; about 63% were women; 49% were White, 19% were Black, 3% were Asian, and 24% were Hispanic patients. The primary outcome was risk for depression after adjusting for comorbidities such as autoimmune and thyroid diseases, Hashimoto thyroiditis, and diabetes. TAKEAWAY: Overall, patients with vitiligo showed an increased risk for depression (adjusted odds ratio [aOR], 1.34; 95% CI, 1.16-1.54) compared with those without vitiligo. Black patients with vitiligo had more than a twofold higher risk for depression (aOR, 2.13; 95% CI, 1.55-2.91) than Black patients without vitiligo. Hispanic patients also had a significantly higher risk for depression (aOR, 1.45; 95% CI, 1.09-1.94), and non-Hispanic patients were also at a higher risk for depression (aOR, 1.29; 95% CI, 1.09-1.52) than Hispanic and non-Hispanic control individuals without vitiligo, respectively. The risk for depression in White individuals (aOR, 1.06; 95% CI, 0.85-1.29) and in Asian individuals with vitiligo (aOR, 0.70; 95% CI, 0.15-2.38) was not significantly increased when compared with White and Asian patients without vitiligo, respectively. IN PRACTICE: 'These findings underscore significant variation in the mental health burden of vitiligo across racial and ethnic groups,' the study authors wrote. 'Black and Hispanic patients with vitiligo,' they added, 'experience significantly elevated depression risk, potentially reflecting greater lesion visibility, cultural stigma, and differences in access to mental health and dermatologic services.' SOURCE: The study was led by Matthew J. Yan, BS, BA, Division of Dermatology, Department of Medicine at the University of California, Los Angeles, and was published online on August 5 in JAAD International. LIMITATIONS: The study did not assess vitiligo lesion visibility, treatment details, or age of onset. Sample sizes for Asian patients were small and could limit generalizability. DISCLOSURES: The study did not receive any funding. One author disclosed receiving research support, advisory, and speaker fees from AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO, UCB, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Regeneron, and Pfizer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.